Bronte Capital Management’s Gossamer Bio GOSS Stock Holding History

Bronte Capital Management’s Portfolio GOSS Stock Details GOSS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$11.2K	Buy	+67,754	New	+$18.9K	﹤0.01%	57

Other funds holding GOSS

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

6CM

683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

DIG

DeepCurrents Investment Group New York $3.3B AUM 12.57% 1-Year Est. Return

CCM

Context Capital Management Lajolla, California $5.15B AUM 1.28% 1-Year Est. Return

WVP

Worth Venture Partners Fort Lee, New Jersey $44.3M AUM 34.55% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return

WAM

Wolverine Asset Management Chicago, Illinois $11.4B AUM 5.65% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

KCM

Kalehua Capital Management Dallas, Texas $174M AUM

Bronte Capital Management's GOSS Position: Q2 2026 in Review

Bronte Capital Management opened a new position in Gossamer Bio (GOSS) in Q2 2026: 67,754 shares worth $11.2K. The stake represents ﹤0.01% of the portfolio and ranks #57 among its holdings.

170 funds tracked by Wall St. Rank hold GOSS as of Q2 2026.

Bronte Capital Management held 67,754 shares of Gossamer Bio worth $11.2K as of Q2 2026.
Gossamer Bio was a new Bronte Capital Management position in Q2 2026.
Gossamer Bio made up ﹤0.01% of Bronte Capital Management's portfolio in Q2 2026, its #57 holding.
170 funds tracked by Wall St. Rank held Gossamer Bio as of Q2 2026.

Based on Bronte Capital Management's 13F filing for Q2 2026, filed 5 Aug 2026.